TOVX

0.04% -0.000100

시간 외 거래: .24 0.015 +6.67%

Theriva Biologics Inc (TOVX)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Theriva Biologics Inc Stock (TOVX) Company Profile

Theriva Biologics Inc

Healthcare (1064)

Biotechnology (596)

301 417 4364

9605 Medical Center Drive, Suite 270, Rockville

최신 SEC 제출 서류

TOVX's Discussions on Twitter

Compare TOVX vs VRTX, MRNA, REGN, ARGX, RVMD

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
TOVX Theriva Biologics Inc	0.225	10.12M	0	-21.46M	-14.40M	-2.5324
VRTX Vertex Pharmaceuticals Inc	503.50	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	203.21	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	726.47	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	912.87	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	207.68	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Theriva Biologics Inc 주식(TOVX)의 최신 뉴스

Theriva Biologics Inc (TOVX) 재무 분석

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc Stock (TOVX) Company Profile

Compare TOVX vs VRTX, MRNA, REGN, ARGX, RVMD

Theriva Biologics Inc 주식(TOVX)의 최신 뉴스

Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásico - GlobeNewswire Inc.

Theriva publishes VCN-01 pancreatic cancer trial data in journal By Investing.com - Investing.com Canada

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Yahoo! Finance Canada

TOVX Should I Buy - Intellectia AI

Theriva Biologics Inc. (TOVX) Peer Comparison – Compare with Others - Value Research

Theriva Biologics Inc. (TOVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Theriva Biologics Inc. (TOVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Theriva Biologics Inc. (TOVX) Key Financial Ratios – Valuation, Profitability & More - Value Research

Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DayConsensus Beat Rate - vinanet.vn

Theriva Biologics(TOVX) Stock Options Chain | Quotes & News - Moomoo

Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportRounding Bottom - vinanet.vn

Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneQuality Factor - vinanet.vn

Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportSentiment Divergence - vinanet.vn

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet

Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria

Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView

Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative

Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView

Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan

Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com

Theriva Biologics 2Q Loss/Shr 7c >TOVX - Moomoo

BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - GlobeNewswire

Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa

Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart

Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria

Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 - GlobeNewswire

Theriva Biologics Expands Stock Incentive and Governance Plans - TipRanks

Theriva Biologics (NYSE American: TOVX) holders back bigger stock plan, warrants - Stock Titan

Theriva Biologics, Inc. Revenue Breakdown – AMEX:TOVX - TradingView

TOVX|Theriva Biologics Inc|Price:0.222|Chg%:+0.012 - TradingKey

Theriva Biologics Inc (TOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Theriva Biologics Inc (TOVX) Cash Flow - TradingKey

TOVX|Theriva Biologics Inc|Price:0.214|Chg%:-0.009 - TradingKey

Theriva Biologics Inc (TOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Theriva Biologics Inc (TOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Theriva Biologics Inc (TOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Theriva Biologics, Inc. Revenue Breakdown – BOATS:TOVX - TradingView

Theriva Biologics Inc (TOVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

TOVX|Theriva Biologics Inc|Price:0.223|Chg%:-0.001 - TradingKey

Theriva Biologics (TOVX) Proxy Filing Summary - Quartr

Theriva Biologics (TOVX) Slides 5% as Selling Pressure Mounts Near Key SupportPCR Extreme - vinanet.vn

Theriva Biologics (TOVX) Declines 5.6% as Stock Tests Key Support LevelsAI Trade Signals - dars.gov.et

symbol__ Stock Quote Price and Forecast - CNN

Theriva Biologics (TOVX) Secures Approval for VIRAGE2 Clinical T - GuruFocus

Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy - Moomoo

Theriva Biologics launches VIRAGE2 metastatic pancreatic trial - TipRanks

Theriva Biologics cleared to start VIRAGE2 trial | TOVX 8-K Filing - Stock Titan

Theriva Biologics Inc (TOVX) 재무 분석

매출

순이익

현금흐름

주당 순 이익

TOVX과 유사한 종목